The Challenge, Promise of Getting Oral COVID Drugs Into Practice

Effective oral therapeutics may be the "holy grail" for COVID treatments, but getting them from into practice can be a labyrinthine process, regardless of the need or desire for the drugs.

Related Keywords

Brazil ,United States ,United Kingdom ,Massachusetts ,Boston ,University Of Southern California ,California ,San Francisco Bay ,San Francisco ,America ,American ,David Boulware ,Jeff Klausner ,Susanna Naggie ,Janet Woodcock ,Paul Sax ,Brandon Shumway ,Barbara Kilian ,Norman Hearst ,Carolyn Bramante ,University Of California ,Parsemus Foundation ,Lancet Global Health ,Medscape Coronavirus Resource Center ,Rainwater Charitable Foundation ,Pfizer ,University Of Minnesota ,Facebook ,Central Valley Indian Health In Clovis ,Division Of Infectious Diseases At Brigham ,National Institutes Of Health ,Drug Administration ,Harvard Medical School ,Infectious Diseases Society Of America ,Duke University ,Coronavirus Resource ,Medscape Medical ,San Francisco Bay Area ,National Institutes ,American Rescue Plan Act ,Central Valley Indian Health ,Infectious Diseases ,Johns Hopkins Medicine ,Infectious Diseases Society ,Cliff Lane ,Public Readiness ,Emergency Preparedness ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Covid 19 Treatment ,Clinical Research ,Clinical Trials ,Linical Studies ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Obsessive Compulsive Disorder Ocd ,Obsessive Compulsive Disorder ,Cd ,Treatment Gu ,